

Filed on behalf of: Corcept Therapeutics, Inc.

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TEVA PHARMACEUTICALS USA, INC.,
Petitioner

v.

CORCEPT THERAPEUTICS, INC.,
Patent Owner

Case PGR2019-00048
U.S. Patent No. 10,195,214

PATENT OWNER SUR-REPLY

TABLE OF CONTENTS

	<u>Page</u>
I. Introduction.....	1
II. Teva’s Reply Confirms That It Cannot Show the Required Reasonable Expectation of Success	2
A. The Reasonable Expectation of Success Argument Advanced in Teva’s Petition Has Been Fully Discredited	2
B. Teva’s Attempt to Change Its Definition of a POSA Fails.....	7
III. Teva’s Focus on the Alleged “Routine” Nature of the Clinical Trials that Led to the Claimed Methods Is Legally and Factually Deficient	10
A. Routine Experimentation Cannot Compensate for a Lack of Reasonable Expectation of Success	10
B. Corcept’s DDI Studies Were Not “Routine”	15
IV. Teva’s Remaining Arguments Fail to Revive its Obviousness Case.....	18
A. Lee Recommended Contraindicating Mifepristone and Strong CYP3A Inhibitors.....	18
B. The Dunnigan Case Report Reinforced the Prior Art Teachings that the Combination of Greater Than 300 mg Mifepristone and Strong CYP3A Inhibitors Would Not Be Safe for Patients.....	19
C. Alleged “Motivation” to Perform a DDI Study Does not Compel a Finding of Obviousness	21
D. The Federal Circuit’s Decision in the <i>Valeant</i> Case Does Not Compel a Finding of Obviousness	23
V. Conclusion	25

TABLE OF AUTHORITIES

Page

Cases

Apotex Inc. v. Celgene Corp.,
IPR2018-00685, Paper 8 (P.T.A.B. Sept. 27, 2018).....20

Apple Inc. v. Qualcomm,
IPR2018-01252, Paper 28 (P.T.A.B. Jan. 22, 2020)19

Eli Lilly & Co. v. Teva Pharm. Int’l.,
IPR2018-01710, Paper 69 (P.T.A.B. Mar. 31, 2020) 11, 14

Honeywell Int’l Inc. v. Mexichem Amanco Holding,
865 F.3d 1348 (Fed. Cir. 2017)..... 11, 21

Intelligent Bio-Sys., Inc. v. Illumina Cambridge Ltd.,
821 F.3d 1359 (Fed. Cir. 2016)20

Otsuka Pharm. Co. v. Sandoz, Inc.,
678 F.3d 1280 (Fed. Cir. 2012)16

Ralph Lauren Corp. v. Lexos Media IP,
IPR2018-01749, Paper 21 (P.T.A.B. Apr. 3, 2020).....15

In re Stepan Co.,
868 F.3d 1342 (Fed. Cir. 2017)7, 11

Tietex Int’l, Ltd. v. Precision Fabrics Grp., Inc.,
IPR2014-01248, Paper 39 (P.T.A.B. Feb. 27, 2016).....14

Valeant Pharm. Int’l, Inc. v. Mylan Pharm. Inc.,
955 F.3d 25 (Fed. Cir. 2020)..... 23-25

Wasica Fin. GmbH v. Cont’l Auto. Sys., Inc.,
853 F.3d 1272 (Fed. Cir. 2017) 10, 15

Statutory Authorities

35 U.S.C. §10315

Rules and Regulations

MPEP 2144.0511

Table of Abbreviations

Corcept	Patent Owner, Corcept Therapeutics, Inc.
DDI	Drug-Drug Interaction
FDA	The United States Food & Drug Administration
ID	Institution Decision
PGR	Post Grant Review
POPR	Patent Owner Preliminary Response
POR	Patent Owner Response
POSA	Person of Skill in the Art
Teva	Petitioner, Teva Pharmaceuticals USA, Inc.

* Unless otherwise noted, all emphasis added throughout brief.

Exhibits

EX	Description
2001	August 2018 Update to the Office Patent Trial Practice Guide, 83 Fed. Reg. 39,989 (Aug. 13, 2018)
2002	Chart Comparing Arguments Made By Petitioner in PGR2019-00048 and in the District Court Litigation
2003	January 16, 2019 Email from U. Everett to Counsel
2004	<i>Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.</i> , No. 18-cv-3632, D.I. 31 (D.N.J. Oct. 23, 2018)
2005	<i>Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.</i> , No. 18-cv-3632, D.I. 73 (D.N.J. June 4, 2019)
2006	R. Pivonello et al., “The Treatment of Cushing’s Disease,” <i>Endocrine Rev.</i> , 36(4):385-486 (2015)
2007	D. Guelho & A. Grossman, “Emerging Drugs for Cushing’s disease,” <i>Exp. Op. on Emerging Drugs</i> , 20(3):463-78 (2015)
2008	M. Fleseriu & S. Petersenn, “New Avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy,” <i>J. Neurooncol.</i> , 114:1-11 (2013)
2009	R.A. Feelders et al., “The burden of Cushing’s disease: clinical and health-related quality of life aspects,” <i>Eur. J. Endocrinol.</i> , 167:311-26 (2012)
2010	“Hyperglycemia in Diabetes,” The Mayo Clinic (Nov. 3, 2018), https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptoms-causes/syc-20373631
2011	D. Cuevas-Ramos et al., “Update on medical treatment for Cushing’s disease,” <i>Clin. Diabetes & Endocrinol.</i> , 2:16 (2016)
2012	M. Fleseriu et al., “A New Therapeutic Approach in the Medical Treatment of Cushing’s Syndrome: Glucocorticoid Receptor Blockade with Mifepristone,” <i>Endocrine Practice</i> , 19(2):313-26 (2013)
2013	O. Heikinheimo et al., “The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action,” <i>Contraception</i> , 68:421-26 (2003)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.